EUCTR2007-002625-77-IT进行中（未招募）不适用
Randomized phase II trial of first line chemoterapy Docetaxel given in combination with Cisplatin for 6 cycles or Docetaxel given in combination with Cisplatin for 3 cycles followed by Docetaxel alone for 3 cycles in patients with advanced non-small-cell lung cancer. - ND
FONDAZIONE ISTITUTO SAN RAFFAELE-G.GIGLIO0 个研究点开始时间: 2007年7月5日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1)Histologically or cytologically confirmed diagnosis of NSCLC;
- •2)Histologic subtypes may include large cell, squamous cell, or adenocarcinoma or a generic cytological diagnosis of NSCLC;
- •3)Patients must have a locoregionally advanced unresectable non metastatic NSCLC Stage IIIB (only N3 supracavicular or T4 for pleural effusion) or Stage IV according to the revised International Staging System;
- •4)Males or females aged between 18 and 70 years;
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1)Prior systemic chemotherapy or immunotherapy. Prior neoadjuvant or adjuvant chemotherapy is allowed if ended at least 12 months before enrollment;
- •2)Prior radiotherapy for NSCLC to measurable lesions. prior radiotherapy (to <_25% of the bone marrow) is allowed in non target lesions. at least 4 weeks must be elapsed since the completion of the radiation therapy and the patient must have all side effects recovered;
- •3)cyto-histological diagnosis of small cell lung cancer;
- •4)patients with symptomatic brain matastases or with leptomeningeal disease;
研究者
相似试验
进行中（未招募）
不适用
Randomised phase II trial on primary chemotherapy with high-dose Methotrexate and high-dose Cytarabine with or without Thiotepa, and with or without Rituximab, followed by brain irradiation vs high-dose chemotherapy supported by autologous stem cells transplantation for immunocompetent patients with newly diagnosed Primary CNS Lymphoma. - IELSG 32EUCTR2009-012432-32-GBniversity Hospital Southampton NHS Foundation Trust126
进行中（未招募）
不适用
Randomized phase II trial on primary chemotherapy with high-dose methotrexate and high-dose cytarabine with or without thiotepa, and with or without rituximab, followed by brain irradiation vs. high-dose chemotherapy supported by autologous stem cells transplantation for immunocompetent patients with newly diagnosed primary cns lymphoma. - IELSG 32newly diagnosed primary CNS lymphoma in immunocompetent patientsMedDRA version: 9.1Level: LLTClassification code 10036685EUCTR2009-012432-32-ITIELSG-International Extranodal Lymphoma Study Group126
进行中（未招募）
不适用
Et randomiseret fase ll studie af primær kemoterapi med højdosis Methotrexat oghøjdosis Cytarabin med eller uden thiotepa og med eller uden Rituximab efterfulgtaf strålebehandling eller højdosis kemoterapi med autolog stamcelletransplantationhos immunkompetente patienter med nydiagnosticeret primært CNS-lymfom.ewly diagnosed Primary CNS LymphomaEUCTR2009-012432-32-DKInternational Extranodal Lymphoma Srudy Group IELSG126
已完成
2 期
Randomized Phase II Trial On Primary Chemotherapy With High-Dose Methotrexate And High-Dose Cytarabine With Or Without Thiotepa, And With Or Without Rituximab, Followed By Brain Irradiation Vs. High-Dose Chemotherapy Supported By Autologous Stem Cells Transplantation For Immunocompetent Patients With Newly Diagnosed Primary CNS LymphomaCentral Nervous System LymphomaDRKS00003763niversitätsklinikum Freiburg, Abt. Med 1, Hämatologie/ Onkologie227
进行中（未招募）
不适用
Randomized phase II trial of second-line chemotherapy with oxaliplatin and docetaxel vs. docetaxel in patients with advanced non-small cell lung cancer (NSCLC)Second-line chemotherapy in advanced non small cell lung cancerMedDRA version: 6.1Level: PTClassification code 10059515EUCTR2004-002539-25-ITIVERSITA' DEGLI STUDI DI UDINE42